What are the next steps for PSMA-PET imaging in prostate cancer?

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

The incorporation of PSMA PET–imaging into a multivariate model enhanced the predictive accuracy for clinically significant prostate cancer in patients in the "PSA gray zone" of 4 to 10 ng/mL.

On this podcast, Bristol Whiles, MD, discusses her urology residency experience at the Kansas University School of Medicine Department of Urology.

The Society of Nuclear Medicine and Molecular Imaging announced a consensus statement on patient selection and appropriate use of the radionuclide therapy 177Lu-PSMA-617 in patients with prostate cancer.

Cohort 3 of the SECuRE trial is exploring the safety and efficacy of a single-dose administration of 12GBq 67Cu SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.